Kana Mizuno, PhD

Clinical Model-Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients. Taylor, ZL; Nadai, T; Irie, K; Tan, WR; Parikh, S; Hosawi, A; Van Hoogdalem, MW; Morales Junior, R; Tang Girdwood, S; Leino, AD; Mizuno, K; Vinks, AA; Mizuno, T. Clinical Pharmacology and Therapeutics. 2026.

Determinants of Eculizumab Response in High-Risk Transplant-Associated Thrombotic Microangiopathy. Jodele, S; Mizuno, K; Sabulski, A; Dandoy, CE; Ramos, KN; Langenberg, L; Luebbering, N; Webster, A; Klink, G; Mclean, S; Davies, SM. Transplantation and Cellular Therapy. 2026; 32(2):s104-s105.

Multiomics Reveal Interferon-Induced Cell Senescence As a Novel Mechanism of Eculizumab Resistance in TA-TMA. Sabulski, A; Webster, A; Mizuno, K; Luebbering, N; Davies, SM; Jodele, S. Transplantation and Cellular Therapy. 2026; 32(2):s594-s595.

A Decade of Precision: PK/PD-Guided Eculizumab Therapy for TA-TMA Management. Klink, G; Mizuno, K; Teusink, A; Mclean, S; Davies, SM; Jodele, S. Transplantation and Cellular Therapy. 2026; 32(2):s615.

Interferon-induced cell senescence as a novel mechanism of eculizumab resistance in transplant associated thrombotic microangiopathy. Webster, A; Mizuno, K; Luebbering, N; Davies, SM; Jodele, S; Sabulski, A. Blood. 2025; 146(Supplement 1):509.

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. Journal of Human Immunity. 2025; 1(CIS2025).

Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Mehta, PA; Nelson, A; Loveless, S; Lane, A; Fukuda, T; Teusink-Cross, A; Elder, D; Lagory, D; Miller, E; Cancelas, JA; Edwards, S; Chihanga, T; Wells, SI; Davies, SM. Blood advances. 2025; 9(8):1927-1939.

Unraveling the Challenges of Non-Responders to the Eculizumab Treatment with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Mizuno, K; Teusink-Cross, A; Sabulski, A; Davies, SM; Jodele, S. Transplantation and Cellular Therapy. 2025; 31(2):s542-s543.

A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA. Jodele, S; Dandoy, CE; Aguayo-Hiraldo, P; Lane, A; Teusink-Cross, A; Sabulski, A; Mizuno, K; Laskin, BL; Freedman, J; Davies, SM. Blood. 2024; 143(12):1112-1123.

Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies. Jodele, S; Mizuno, K; Sabulski, A; Vinks, AA. Clinical Pharmacology and Therapeutics. 2023; 114(3):511-514.